P. Zhou

Development of selective mono or dual PROTAC degrader probe of CDK isoforms.

Jijun Cheng, Yongmei Xie, Lifeng Zhao, 2019, European journal of medicinal chemistry.

Intestinal dysbiosis exacerbates the pathogenesis of psoriasis-like phenotype through changes in fatty acid metabolism

Jiadong Yu, Yifan Zhou, Hong Zhou, 2021, Signal Transduction and Targeted Therapy.

Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of PARP1 for Treating Cancers.

Lifeng Zhao, Yong Chen, Jie Yang, 2020, Journal of medicinal chemistry.

Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.

J. Yu, Xinghai Li, Guoyi Yan, 2019, European journal of medicinal chemistry.

Metabolically Stable Diphenylamine Derivatives Suppress Androgen Receptor and BET Protein in Prostate Cancer.

Xinghai Li, J. Yu, Guoyi Yan, 2020, Biochemical pharmacology.

Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.

Xinghai Li, Mingxing Hu, J. Yu, 2019, European journal of medicinal chemistry.